Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T20:37:30.724Z.
Calculation as of: 2026-10-06T20:37:30.724Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b626f321e8bf7fc1aa576344fb562ad2ba7a1b85fa36d8388ebfe6a76482c652
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-09-30.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$29771.00
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$70884.00
EV/Sales Ratio
N/A
TTM Avg
159.76x
3Y Avg
159.76x
5Y Avg
159.76x
Market Cap
$110112.00
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$378849.00
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NewGenIvf Group Limited (NIVF) | $6235.00 | N/A | N/A | N/A | N/A |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $29771.00 | N/A | N/A | N/A | N/A |
| Zhongchao Inc. (ZCMD)vs › | $30389.00 | N/A | N/A | N/A | N/A |
| Akanda Corp. (AKAN)vs › | $61172.00 | N/A | N/A | N/A | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $70884.00 | N/A | 159.76x | 159.76x | 159.76x |
| Psyence Biomedical Ltd. (PBM)vs › | $95475.00 | N/A | N/A | N/A | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $110112.00 | N/A | N/A | N/A | N/A |
| SciSparc Ltd. (SPRC)vs › | $250443.00 | N/A | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $378849.00 | N/A | N/A | N/A | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $403887.00 | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2024-09-30 | 7030.03x |
| 2024-09-27 | 6460.60x |
| 2024-09-26 | 6595.20x |
| 2024-09-25 | 6895.44x |
| 2024-09-24 | 6025.77x |
| 2024-09-23 | 6243.19x |
| 2024-09-20 | 6698.73x |
| 2024-09-19 | 6533.08x |
| 2024-09-18 | 7071.45x |
| 2024-09-17 | 6936.85x |
| 2024-09-16 | 7216.39x |
| 2024-09-13 | 7237.10x |
| 2024-09-12 | 7247.45x |
| 2024-09-11 | 7247.45x |
| 2024-09-10 | 6988.62x |
| 2024-09-09 | 7247.45x |
| 2024-09-06 | 7050.74x |
| 2024-09-05 | 7299.22x |
| 2024-09-04 | 7661.58x |
| 2024-09-03 | 8655.49x |
| 2024-08-30 | 8903.97x |
| 2024-08-29 | 9111.03x |
| 2024-08-28 | 9359.51x |
| 2024-08-27 | 9835.76x |
| 2024-08-26 | 10011.76x |
| 2024-08-23 | 11740.76x |
| 2024-08-22 | 9628.70x |
| 2024-08-21 | 8852.20x |
| 2024-08-20 | 8603.72x |
